Senior Director, Global Medical Affairs & Evidence Generation, empasiprubart; MMN

Join us as we transform immunology and deliver medicines that help autoimmune patients get their lives back. argenx is preparing for multi-dimensional expansion to reach more patients through a rich pipeline of differentiated assets, led by VYVGART, our first-in-class neonatal Fc receptor blocker approved for the treatment of gMG, and with the potential to treat patients across dozens of severe autoimmune diseases.

We are building a new kind of biotech company, one that maintains its roots as a science-based start-up and pushes our commitment to innovate across all corners of our business. We strive to inspire and grow our company, our partnerships, our science, and our people, because when we do, we deliver more for patients. The Global Medical Affairs and Evidence Generation (MAEG) group delivers ambitious, patient-focused cross-regional and cross-indication medical strategies, driving data generation and dissemination, to maximize patient benefit from argenx products.

The MAEG Senior Director will provide strategic and hands‑on medical leadership for empasiprubart in multifocal motor neuropathy (MMN), with a focus on medical launch readiness and evidence generation. Reporting to the empasiprubart Medical Affairs and Evidence Generation Asset Strategy Lead, the role will work in close partnership with the MMN Medical Director and regional MAEG teams, adding complementary launch expertise and capacity.

The Senior Director will lead global medical work streams from strategy through execution, acting as a co‑owner across a network of teams to translate scientific and stakeholder insights into actions that accelerate patient impact.

• Lead global MMN medical launch‑readiness work streams in partnership with cross‑functional and regional teams, empowering teams to co‑create clear deliverables, milestones, dependencies, and measures of readiness, while proactively resolving barriers and escalating risks with proposed solutions
• Translate prioritized MMN evidence gaps into a data‑driven global evidence strategy, co‑creating with the MMN Medical Director to align scientific objectives, feasibility, timelines, and resources
• Lead the medical strategy and scientific oversight of evidence‑generation initiatives, challenging the status quo and applying innovative approaches to address complex evidence needs and improve outcomes for patients in partnership with Clinical Development, RWE, Health Economics and Outcomes Research (HEOR), and regional MAEG teams
• Operate as part of a connected network of teams, co‑creating with regional and country MAEG colleagues to translate global strategy into locally relevant plans, integrate regional insights, and develop shared scientific resources that enable effective local execution
• Build trusted partnerships with experts, healthcare and patient organizations to listen, learn, and co‑create evidence, education, and insights that shape patient‑centered Medical Affairs priorities
• Identify and prioritize MMN evidence and education needs across the patient journey, including diagnosis, treatment patterns, disease burden, functional outcomes and treatment burden, and translate these insights into actionable medical strategies
• Partner with scientific communications to support development and execution of publication plans for impactful data dissemination and medical education strategies
• Develop and continuously maintain the highest scientific and medical expertise with relevant diseases and products and be acknowledged internally and externally as an expert
• Seek diverse perspectives with curiosity and humility, synthesizing insights from scientific exchange, regional teams, congresses, advisory boards, and patient communities into…